close

Neurocrine Biosciences, Inc. engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders. Its products in clinical development comprise Elagolix, a Phase II product for Endometriosis; CRF1 Antagonist, a phase II product for mood disorders; CRF2 Peptide Agonist, a phase II drug for Cardiovascular related diseases; CRF1 Antagonist, a Phase I product for treating Mood Disorders and Irritable Bowel Syndrome; and Elagolix, a Phase I product for treating Benign Prostatic Hyperplasia and Uterine Fibroids. The company's research programs include Vesicular Monoamine Transporter 2 Inhibitor for movement disorders and schizophrenia; Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. It has strategic alliances with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is based in San Diego, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	8.16
Volume	961870
Volume Avg	517579
52 Week High	9.98
52 Week Low	5.42
PE	11.93
PE (group average)	39
EPS Year	0.67
EPS change Q/Q	0%
EPS change Q/Q Yr ago	-1000%
EPS change Q/Q next Q est	-1000%
EPS change Y/Y	1000%
REV change Q/Q	-8.76%
REV change Q/Q Yr ago	1462.5%
EPS next Q est	-0.03
EPS next Y est	-0.49
Divident Annual	0.00
Dividend Yield	0%